LARIMAR THERAPEUTICS, INC. Available-for-sale Securities, Gross Realized Gain (Loss)
LARIMAR THERAPEUTICS, INC. (LRMR) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $341.00 thousand for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-05-14.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2015-05-14
- LARIMAR THERAPEUTICS, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2015-03-31 was $341.00K.
- LARIMAR THERAPEUTICS, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2014 was $225.00K.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|
| 2015-03-31 | $341.00K 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $225.00K 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |